Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.37 extracted from

  • Inoue, Y.; Omodani, T.; Shiratake, R.; Okazaki, H.; Kuromiya, A.; Kubo, T.; Sato, F.
    Development of a highly water-soluble peptide-based human neutrophil elastase inhibitor; AE-3763 for treatment of acute organ injury (2009), Bioorg. Med. Chem., 17, 7477-7486.
    View publication on PubMed
Search for more literature for 3.4.21.37

Inhibitors

Inhibitors Comment Organism Structure
additional information synthesis of a series of peptide-based transition-state human neutrophil elastase inhibitors with N-terminal acidic moieties, evaluation of in vitro and in vivo inhibitory activities, overview Homo sapiens
N-([3-(carboxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]acetyl)-L-valyl-N-[(3R,S)1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]acetyl)-L-valyl-N-[(3S)-1-(benzylamino)-4-methyl-1,2-dioxopentan-3-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]acetyl)-L-valyl-N-[(3S)-1-methoxy-4-methyl-1,2-dioxopentan-3-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2,4-dioxoimidazolidin-1-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2,5-dioxoimidazolidin-1-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2,6-dioxotetrahydropyrimidin-1(2H)-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2-oxoimidazolidin-1-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2-oxoimidazolidin-1-yl]acetyl)-L-valyl-N-[(3R)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-2-oxoimidazolidin-1-yl]acetyl)-L-valyl-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]-L-prolinamide i.e. AE-3763, it effects in lipopolysaccharide-induced lung injury model of lung edema and leukocyte infiltration, overveiw Homo sapiens
N-([3-(carboxymethyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([3-(carboxymethyl)-5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([4-(carboxymethoxy)phenoxy]acetyl)-L-valyl-N-[(benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([4-(carboxymethyl)-2,3-dioxopiperazin-1-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([4-(carboxymethyl)-2,3-dioxopiperazin-1-yl]acetyl)-L-valyl-N-[(3S)-1-(benzylamino)-4-methyl-1,2-dioxopentan-3-yl]-L-prolinamide
-
 Homo sapiens
N-([4-(carboxymethyl)-2,3-dioxopiperazin-1-yl]acetyl)-L-valyl-N-[(3S)-1-methoxy-4-methyl-1,2-dioxopentan-3-yl]-L-prolinamide
-
 Homo sapiens
N-([4-(carboxymethyl)-2,5-dioxopiperazin-1-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([4-(carboxymethyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([4-(carboxymethyl)-6-methyl-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-([4-(carboxymethyl)piperazin-1-yl]acetyl)-L-valyl-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]-L-prolinamide
-
 Homo sapiens
N-[(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetyl]-L-valyl-N-[(3R,S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]-L-prolinamide
-
 Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
commercial preparation
-
 Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
N-methoxysuccinyl-Ala-Ala-Pro-Val-4-nitroanilide + H2O
-
 Homo sapiens N-methoxysuccinyl-Ala-Ala-Pro-Val + 4-nitroaniline
-
 ?

Synonyms

Synonyms Comment Organism
neutrophil elastase
-
 Homo sapiens

Temperature Optimum [°C]

Temperature Optimum [°C] Temperature Optimum Maximum [°C] Comment Organism
37
-
 assay at Homo sapiens

pH Optimum

pH Optimum Minimum pH Optimum Maximum Comment Organism
7
-
 assay at Homo sapiens